Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics

Patent metadata

Field	Value
Publication number	US-9567361-B2
Application number	US-201213469499-A
Country	US
Kind code	B2
Filing date	May 11, 2012
Priority date	May 13, 2011
Publication date	Feb 14, 2017
Grant date	Feb 14, 2017

Abstract

The invention provides compositions and methods for utilizing synthetic human milk oligosaccharides as prebiotics.

First claim

What is claimed:

1. A method for stimulating the growth of an exogenously administered probiotic bacterium in a gastrointestinal tract of a mammalian subject, comprising:
administering to said subject a composition comprising an oligosaccharide, wherein said oligosaccharide consists of (a) purified 2′-fucosyllactose (2′-FL), (b) purified 3-fucosyllactose (3-FL), (c) purified lactodifucotetraose (LDFT), or (d) a combination thereof, wherein the composition further comprises a probiotic bacterium selected from the group consisting of Bifidobacterium bifidum, Bacteroides fragilis, Bacteroides thetaiotaomicron, Lactobacillus acidophilus, Lactobacillus rhamnosus, Bacteroides vulgatus, Lactococcus lactis , and Streptococcus thermophilus , wherein said 2′-FL, said 3-FL, or said LDFT is at least 95%, 98%, or 99% pure, and wherein said oligosaccharide selectively stimulates the growth of said probiotic bacterium.

2. The method of claim 1 , wherein the local pH in said gastrointestinal tract is decreased following administration of said composition.

3. The method of claim 1 , wherein the local lactate or lactic acid concentration in said gastrointestinal tract is increased following administration of said composition.

4. The method of claim 1 , wherein the growth of a pathogenic bacterium in said gastrointestinal tract is inhibited following administration of said composition.

5. The method of claim 1 , wherein said composition comprises between 0.01 g 2′ FL and 1 g 2′-FL per gram of composition.

6. The method of claim 4 , wherein said pathogenic bacterium is selected from the group consisting of Clostridium histolyticum, Clostridium difficile, Clostridium perfringens, Enterobacter aerogenes, Listeria monocytogenes, Staphylococcus aureus, Salmonella enterica, Yersinia enterocolitica , enterotoxigenic E. coli , and enteropathogenic E. coli.

7. The method of claim 1 , wherein said subject is an infant.

8. The method of claim 1 , wherein said composition is in the form of an infant formula.

9. The method of claim 1 , wherein said composition is provided in dry milk, in mashed rice, in a banana, in a porridge, or in a gruel.

10. A method for stimulating the growth of an exogenously administered probiotic bacterium in a gastrointestinal tract of a mammalian subject, comprising:
administering to said subject a composition comprising (a) purified 2′-fucosyllactose (2′-FL), (b) purified 3-fucosyllactose (3-FL), (c) purified lactodifucotetraose (LDFT), or (d) a combination thereof, wherein said 2′-FL, said 3-FL, or said LDFT is at least 95%, 98%, or 99% pure, wherein said oligosaccharide selectively stimulates the growth of said probiotic bacterium and wherein the exogenously administered probiotic bacterium comprises a probiotic bacterium selected from the group consisting of Bifidobacterium bifidum, Bacteroides fragilis, Bacteroides thetaiotaomicron, Lactobacillus acidophilus, Lactobacillus rhamnosus, Bacteroides vulgatus, Lactococcus lactis , and Streptococcus thermophilus.

11. A method for stimulating the growth of an exogenously administered probiotic bacterium in a gastrointestinal tract of a mammalian subject, comprising:
administering to said subject a composition comprising 2′-fucosyllactose (2′-FL), a probiotic bacterium selected from the group consisting of Bifidobacterium bifidum, Bacteroides fragilis, Bacteroides thetaiotaomicron, Lactobacillus acidophilus, Lactobacillus rhamnosus, Bacteroides vulgatus, Lactococcus lactis , and Streptococcus thermophilus , and a pharmaceutically-acceptable excipient or inactive ingredient, wherein said 2′-FL is at least 95%, 98%, or 99% pure, and wherein said 2′-FL selectively stimulates the growth of said probiotic bacterium.

12. The method of claim 1 , wherein said probiotic bacterium is selected from the group consisting of Bifidobacterium bifidum BB-12, Lactobacillus acidophilus RC-14 , Lactobacillus acidophilus NCFM, Lactobacillus acidophilus CL 1285, Lactobacillus rhamnosus GG, and Lactobacillus rhamnosus GR-1.

13. The method of claim 10 , wherein said probiotic bacterium is selected from the group consisting of Bifidobacterium bifidum BB-12, Lactobacillus acidophilus RC-14 , Lactobacillus acidophilus NCFM, Lactobacillus acidophilus CL 1285, Lactobacillus rhamnosus GG, and Lactobacillus rhamnosus GR-1.

14. The method of claim 1 , wherein said probiotic bacterium further comprises Bifidobacterium infantis or Bifidobacterium longum.

15. The method of claim 1 , wherein said composition comprises yogurt or a probiotic beverage.

16. The method of claim 1 , wherein said probiotic bacterium is Bacteroides fragilis, Bacteroides thetaiotaomicron , or Bacteroides vulgatus.

17. The method of claim 1 , wherein said composition comprises a weaning food.

18. The method of claim 1 , wherein said mammalian subject is not an infant.

19. The method of claim 18 , wherein said mammalian subject is a child.

20. The method of claim 18 , wherein said mammalian subject is an adult.

21. The method of claim 6 , wherein said pathogenic bacterium is selected from the group consisting of Enterobacter aerogenes, Listeria monocytogenes, Staphylococcus aureus, Salmonella enterica , and Yersinia enterocolitica.

Assignees

• Newburg David S
• Mccoy John M
• Merighi Massimo
• Heidtman Matthew Ian
• Yu Zhuoteng
• Glycosyn LLC
• Trustees Boston College

Inventors

• Newburg David S
• Mccoy John M
• Merighi Massimo
• Heidtman Matthew Ian
• Yu Zhuoteng

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P1/14

  Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A23L33/10

  using additives (addition of substantially indigestible substances A23L33/21) · CPC title